Drug Trials News for September 2010

Fostamatinib shows positive response in rheumatoid arthritis patients

AstraZeneca’s new oral syk inhibitor, fostamatinib (R788), significantly improves outcomes of patients with rheumatoid arthritis who respond inadequately to methotrexate, according to phase II study data.
22 September, 2010

Cancer Research UK and AstraZeneca to trial first-of-kind drug

Cancer Research UK and Cancer Research Technology have reached an agreement with AstraZeneca to take compound AZD-3965, a first-of-its-kind experimental drug that could treat a range of cancers, into clinical trial.
13 September, 2010

Study shows PRADAXA reduces stroke risk Study shows PRADAXA reduces stroke risk

Newly published sub-group analysis from the landmark RE-LY® study has shown dabigatran etexilate significantly reduces the risk of stroke compared to warfarin, irrespective of centre-based international normalized ratio control.
13 September, 2010

IMP321 trial benefits 90 per cent of patients

A recent clinical research paper indicates that IMP321 combined with paclitaxel has achieved clinical benefit in 90 per cent of patients in first-line metastatic breast cancer.
09 September, 2010

Drug Trials News for September 2010

Drug Trials News Archive

Fostamatinib shows positive response in rheumatoid arthritis patients Fostamatinib shows positive response in rheumatoid arthritis patients

Cancer Research UK and AstraZeneca to trial first-of-kind drug Cancer Research UK and AstraZeneca to trial first-of-kind drug

Study shows PRADAXA reduces stroke risk Study shows PRADAXA reduces stroke risk

IMP321 trial benefits 90 per cent of patients IMP321 trial benefits 90 per cent of patients

Fostamatinib shows positive response in rheumatoid arthritis patients

Cancer Research UK and AstraZeneca to trial first-of-kind drug

IMP321 trial benefits 90 per cent of patients